Second phase 3 study of CaPre in patients with severe hypertriglyceridemia
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Omega-3 phospholipid (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Sponsors Acasti Pharma
- 06 Jun 2017 According to an Acasti Pharma media release, the company plans to initiate this study in the second half of 2017.
- 05 Apr 2017 New trial record
- 30 Mar 2017 Data from this and another phase III trial (CT profile 700272010) will support the New Drug Application (NDA) for CaPre for the treatment of hypertriglyceridemia.